Fulcrum Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fulcrum Therapeutics (FULC).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

3Buy

5Hold

3Sell

Consensus RatingHold# Analysts11Avg. Consensus PT$8Upside to Avg. PT+119.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 3, 2026	JP Morgan	—	Downgrade	Overweight→Underweight	—
Jun 2, 2026	Stifel	James Condulis	Downgrade	Buy→Hold	$25→$3
Jun 2, 2026	Piper Sandler	Edward Tenthoff	Downgrade	Overweight→Underweight	$23→$3
Jun 2, 2026	Truist Securities	Gregory Renza	Downgrade	Buy→Hold	$17→$4
Jun 2, 2026	Leerink Partners	Joseph Schwartz	Downgrade	Outperform→Market Perform	$24→$4
Jun 2, 2026	HC Wainwright & Co.	Andrew S. Fein	Downgrade	Buy→Neutral	$25→$3
Jan 12, 2026	JP Morgan	—	Initiate	Overweight	$20
Dec 11, 2025	Truist Securities	Gregory Renza	PT Raise	Buy	$14→$18
Dec 9, 2025	B of A Securities	Tazeen Ahmad	PT Raise	Underperform	$6→$7
Dec 8, 2025	RBC Capital	Luca Issi	PT Raise	Sector Perform	$7→$10
Dec 8, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$15→$24
Dec 8, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$16→$23
Dec 8, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$18→$25
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$14
Nov 24, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$12→$18
Oct 30, 2025	RBC Capital	Luca Issi	PT Raise	Sector Perform	$5→$7
Oct 30, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$13→$16
Oct 20, 2025	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$12
Jul 30, 2025	RBC Capital	Luca Issi	PT Raise	Sector Perform	$4→$5
Jul 29, 2025	HC Wainwright & Co.	Andrew Fein	Upgrade	Neutral→Buy	$4→$12

Analyst Ratings News

PRO
JP Morgan Downgrades Fulcrum Therapeutics to Underweight

JP Morgan downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight.

Benzinga Newsdesk

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.

Avi Kapoor

PRO
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.

Benzinga Newsdesk

PRO
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.

Benzinga Newsdesk

PRO
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.

Benzinga Newsdesk

Fulcrum Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Fulcrum Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Downgrades Fulcrum Therapeutics to Underweight

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PRO
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

PRO
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

PRO
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

PRO
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

People Also Watch

People Also Watch

Fulcrum Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Fulcrum Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Downgrades Fulcrum Therapeutics to Underweight

This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PROStifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

PROPiper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

PROTruist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

PROLeerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

People Also Watch

People Also Watch

PRO
JP Morgan Downgrades Fulcrum Therapeutics to Underweight

PRO
Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

PRO
Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

PRO
Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

PRO
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4